drugset / Trial / NCT00963937

Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

NCT00963937

Phase 3 Completed 178 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.

Timeline

Start
2009-09-28
Primary completion
2010-12-01
Completion
2010-12-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sumatriptan Unknown 25 mg Oral
Comparator Sumatriptan Unknown 50 mg Oral

Indications